Sickle Cell Anemia Therapeutics Market Size Share Trends Forecast 2026

SEATTLE - April 26, 2021 - PRLog -- Increasing occurrence of the disease especially in the Africa region will drive the sickle cell anemia therapeutics market

There is a growing need of early detection and prevention of curable diseases especially among the adults. This is going to be a key opportunity in the Sickle Cell Anemia Therapeutics Market as the percentage of adult population is increasing on a daily basis owing to the rise in life expectancy among the global population. Additionally, the demand for safe and efficacious treatments is gaining prevalence in the market. This factor coupled with unmet medical needs among the patients will fuel the growth of the global sickle cell anemia therapeutics industry.

Manufacturers around the world are competing on the availability of technologically advanced drugs for the treatment of sickle cell anemia. Key players operating in the global sickle cell anemia therapeutics market are Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics.Some of the other manufacturers are Daiichi Sankyo, Novartis Pharmaceuticals, Bluebird Bio, HemaQuest Pharmaceuticals Inc., Emmaus Medical, HemaQuest Pharmaceuticals, Baxter, and Merck Sharp & Dohme.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/161

According to Center for Disease Control and Prevention, as of 2016, around 100,000 people in the U.S. are affected by sickle cell diseases or SCDs. Sickle cell diseases are very common among black or African Americans. Around 1 in 13 babies belonging to the race are born with sickle cell diseases.

The National Center for Biotechnology Information says that sickle cell anemia is one of the most common hereditary hematological diseases among humans. Annually, around 250,000 children are born with the disease and it is among the most occurring epidemiological genetic diseases worldwide.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/sickle-cell-anemia-therapeutics-market-161

Key Developments

Research and development of novel technologies that may aid in treatment of sickle cell anemia is expected to boost the market growth. The novel technology is expected to improve the monitoring of sickle cell disease.

However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease,  failed to achieve its primary or key secondary efficacy endpoints.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/161